• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Unity Biotechnology Inc.

    3/7/25 4:40:41 PM ET
    $UBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UBX alert in real time by email
    S-8 1 ubx-s8-20250307.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 7, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    Unity Biotechnology, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of

    incorporation or organization)

     

     

    26-4726035

    (I.R.S. Employer

    Identification No.)

    285 East grand Avenue

    South San Francisco, CA

    (Address of Principal Executive Officer)

     

     

    94080

    (Zip Code)

     

    2018 Incentive Award Plan

    2018 Employee Stock Purchase Plan

    (Full title of the plan)

    Anirvan Ghosh, Ph.D. Chief Executive Officer

    Unity Biotechnology, Inc.

    285 East Grand Avenue
    South San Francisco, CA 94080

    (Name and address of agent for service)

     

    (650) 416-1192

    (Telephone number, including area code, of agent for service)

     

     

     

    Copy to:

     

    Alexander Nguyen, Esq.

    Chief Legal Officer and Corporate Secretary

    Unity Biotechnology, Inc.

    285 East Grand Avenue

    South San Francisco, CA 94080

    Telephone: (650) 416-1192

    Facsimile: (415) 656-4371

     

    Joshua M. Dubofsky, Esq.

    Erica Kassman, Esq.

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, CA 94025

    Telephone: (650) 463-2631

    Facsimile: (714) 755-8290

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    Proposed sale to take place as soon after the effective date of the

    registration statement as awards under the plans are exercised and/or vest.

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 1,011,912 shares of the Registrant’s common stock, par value $0.0001 per share, issuable under the following employee benefit plans for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-278679, 333-270567, 333-263576, 333-254619, 333-237088, 333-230086, and 333-224726) are effective: (i) the 2018 Incentive Award Plan, as a result of the operation of an automatic annual increase provision therein, which added 843,260 shares of common stock and (ii) the 2018 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 168,652 shares of common stock.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON

    FORM S-8

    Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Commission on May 7, 2018 (File No. 333-224726), March 6, 2019 (File No. 333-230086), March 11, 2020 (File No. 333-237088) and March 23, 2021 (File No. 333-254619), March 15, 2022 (File No. 333-263576), March 15, 2023 (File No. 333-270567), and April 15, 2024 (File No. 333-278679) are incorporated by reference herein to the extent not modified or superseded hereby or by any subsequently filed document, except for Item 8, which is being updated by this Registration Statement on Form S-8.

     

     


     

    Item 8. Exhibits.

     

    Incorporated by Reference

     

     

     

     

    Filed Herewith

    Exhibit
    Number

     

    Exhibit Description

    Form

     

    Date

     

    Number

     

     

      4.1

     

    Amended and Restated Certificate of Incorporation of Unity Biotechnology, Inc.

     

    8-K

     

    5-7-18

     

    3.1

     

     

      4.2

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation of Unity Biotechnology, Inc.

     

    8-K

     

    10-19-22

     

    3.1

     

     

      4.3

     

    Amended and Restated Bylaws of Unity Biotechnology, Inc.

     

    10-K

     

    4-15-24

     

    3.3

     

     

      4.4

     

    Form of Common Stock Certificate.

     

    10-Q

     

    11-8-22

     

    4.2

     

     

      5.1

     

    Opinion of Latham & Watkins LLP.

     

     

     

     

     

     

     

    X

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

    X

    23.2

     

    Consent of Latham & Watkins LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

    X

    24.1

     

    Power of Attorney. Reference is made to the signature page to the Registration Statement.

     

     

     

     

     

     

     

    X

    99.1(a)#

     

    2018 Incentive Award Plan.

     

    S-8

     

    5-7-18

     

    99.2(a)

     

     

    99.1(b)#

     

    Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Incentive Award Plan.

     

    S-1

     

    4-5-18

     

    10.4(b)

     

     

    99.1(c)#

     

    Form of Restricted Stock Award Grant Notice under the 2018 Incentive Award Plan.

     

    S-1

     

    4-5-18

     

    10.4(c)

     

     

    99.1(d)#

     

    Form of Restricted Stock Unit Award Grant Notice under the 2018 Incentive Award Plan.

     

    S-1

     

    4-5-18

     

    10.4(d)

     

     

    99.2#

     

    2018 Employee Stock Purchase Plan.

     

    S-8

     

    5-7-18

     

    99.3

     

     

    99.3(a)#

     

    2020 Employment Inducement Incentive Award Plan

     

    S-8

     

    3-20-20

     

    99.3(a)

     

     

    99.3(b)#

     

    Amendment to 2020 Employment Inducement Incentive Award Plan

     

    S-8

     

    11-24-20

     

    99.3(b)

     

     

    99.3(c)#

     

    Second Amendment to 2020 Employment Inducement Incentive Award Plan

     

    S-8

     

    3-15-23

     

    99.3(c)

     

     

    99.3(d)#

     

    Form of Stock Option Agreement under the 2020 Employment Inducement Incentive Award Plan, as amended

     

    S-8

     

    3-20-20

     

    99.3(d)

     

     

    99.3(e)#

     

    Form of Restricted Stock Unit Award Agreement under the 2020 Employment Inducement Incentive Award Plan, as amended

     

    S-8

     

    3-20-20

     

    99.3(e)

     

     

    99.3(f)#

     

    Form of Performance Stock Unit Award Agreement under the 2020 Employment Inducement Incentive Award Plan, as amended

     

    S-8

     

    3-20-20

     

    99.3(f)

     

     

    99.3(g)#

     

    Form of Stock Award Agreement under the 2020 Employment Inducement Incentive Award Plan, as amended

     

    S-8

     

    3-20-20

     

    99.3(g)

     

     

    107

     

    Filing Fee Table

     

     

     

     

     

     

     

    X

     

     


     

    # Indicates management contract or compensatory plan.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California.

     

     

    Unity Biotechnology, Inc.

     

     

     

    Date: March 7, 2025

    By:

     /s/ Anirvan Ghosh

     

     

    Anirvan Ghosh, Ph.D.

    Chief Executive Officer

     

     

     


     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Anirvan Ghosh, Ph.D., Alexander Nguyen, and Lynne Sullivan, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on behalf of the Registrant, in the capacities and on the dates indicated.

    Signature

    Title

    Date

     

     

     

    /s/ Anirvan Ghosh

    Anirvan Ghosh, Ph.D.

    Chief Executive Officer and Director

    (Principal Executive Officer)

    March 7, 2025

     

     

     

    /s/ Lynne Sullivan

    Lynne Sullivan

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

     

    March 7, 2025

    /s/ Keith R. Leonard Jr.

    Keith R. Leonard Jr.

    Chairman

     

    March 7, 2025

     

     

     

    /s/ Paul L. Berns

    Paul L. Berns

    Director

    March 7, 2025

     

     

     

    /s/ Nathaniel E. David

    Nathaniel E. David, Ph. D.

    Director

    March 7, 2025

     

     

     

    /s/ Gilmore O’Neill

    Gilmore O'Neill, M.B.

    Director

    March 7, 2025

     

     

     

    /s/ Margo Roberts

    Margo Roberts, Ph. D.

    Director

    March 7, 2025

     

     

     

     

     

    /s/ Michael P. Samar

     

    Director

     

    March 7, 2025

    Michael P. Samar

     

     

     

     

     

     

     

    /s/ Camille D. Samuels

     

    Director

     

    March 7, 2025

    Camille D. Samuels

     

     

     

     

     

     

     

     

     


    Get the next $UBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UBX

    DatePrice TargetRatingAnalyst
    8/22/2024$8.00Buy
    Rodman & Renshaw
    11/16/2023$2.00 → $4.00Neutral → Outperform
    Wedbush
    1/4/2022$4.00Neutral → Buy
    Roth Capital
    1/4/2022Neutral → Buy
    ROTH Capital
    11/10/2021$5.00 → $7.00Neutral → Buy
    Mizuho
    6/28/2021Sell → Buy
    Citigroup
    6/28/2021$6.00Sell → Buy
    Citigroup
    More analyst ratings

    $UBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

      SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah. ARVO 2025 Presentation Details: Title: Safety and Efficacy of Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b TrialsPresentation Number: 4014 Session: Diabetic Macular Edema: Anti-VEGF Date & Time: Wednesday, May 7,

      5/1/25 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

      SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal NEJM Evidence published results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). As reported in the article titled, "Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema," the results suggested that the selective clearance of senescent cells in the retina provided disease-modifying and long-lasting improvements in vision in patients with DME, supporting the potential of UBX1325 as a novel

      4/23/25 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

      SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax) showed vision improvements generally comparable to the aflibercept control, but the study did not meet the primary endpoint of statistical non-inferiority to aflibercept based on BCVA average at weeks 20 and 24. UBX1325 wa

      4/22/25 4:29:59 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Unity Biotechnology with a new price target

      Rodman & Renshaw initiated coverage of Unity Biotechnology with a rating of Buy and set a new price target of $8.00

      8/22/24 7:37:56 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unity Biotechnology upgraded by Wedbush with a new price target

      Wedbush upgraded Unity Biotechnology from Neutral to Outperform and set a new price target of $4.00 from $2.00 previously

      11/16/23 7:43:07 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unity Biotechnology upgraded by Roth Capital with a new price target

      Roth Capital upgraded Unity Biotechnology from Neutral to Buy and set a new price target of $4.00

      1/4/22 12:07:50 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Leadership Updates

    Live Leadership Updates

    See more
    • UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

      SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and development and chief medical officer at Bausch + Lomb, has been appointed to the Company's board of directors and as a member of its science committee. "Dr. Hashad is a highly respected leader in ophthalmology whose expertise will be invaluable as we prepare for the upcoming Phase 2b ASPIRE 24-week data readout and optimize our strategy to potentially advance UBX1325 to late-stage development," said Anirvan Ghosh, Ph.

      3/10/25 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

      SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVRE for geographic atrophy as chief medical officer at Apellis Pharmaceuticals. "Dr. Grossi's extensive experience in clinical strategy and a successful track record of advancing novel ophthalmolo

      1/6/25 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

      SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company's corporate and product strategies. "Alicia's impressive experience in ophthalmology product planning, commercial strategy, and scaling cross-functional teams will be instrumental in fortifying our strategies and capitalizing on the significant opportunity of UBX1325 to transform the treatment landscape for diabetic macular edema (DME)," said Anirvan Ghosh, Ph.

      7/22/24 8:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    SEC Filings

    See more
    • Unity Biotechnology Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Leadership Update, Financial Statements and Exhibits

      8-K - Unity Biotechnology, Inc. (0001463361) (Filer)

      5/5/25 8:00:09 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Unity Biotechnology Inc.

      10-Q - Unity Biotechnology, Inc. (0001463361) (Filer)

      4/22/25 4:31:19 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Unity Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Unity Biotechnology, Inc. (0001463361) (Filer)

      4/22/25 4:30:08 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CLO and Head of Ops Nguyen Alexander Hieu sold $18,388 worth of shares (17,852 units at $1.03), decreasing direct ownership by 27% to 48,753 units (SEC Form 4)

      4 - Unity Biotechnology, Inc. (0001463361) (Issuer)

      4/3/25 4:17:03 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO & Head of Corp. Dev. Sullivan Lynne Marie sold $22,523 worth of shares (21,867 units at $1.03), decreasing direct ownership by 18% to 98,905 units (SEC Form 4)

      4 - Unity Biotechnology, Inc. (0001463361) (Issuer)

      4/3/25 4:16:04 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Ghosh Anirvan sold $99,701 worth of shares (96,797 units at $1.03), decreasing direct ownership by 39% to 153,454 units (SEC Form 4)

      4 - Unity Biotechnology, Inc. (0001463361) (Issuer)

      4/3/25 4:15:04 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Financials

    Live finance-specific insights

    See more
    • UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

      Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior to aflibercept at 7 out of 10 time points in a pre-specified population with moderately aggressive disease UNITY to host investor call with retinal expert Robert B. Bhisi

      3/24/25 7:01:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

      A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any additional injections through 48 weeks Retinal structure, as measured by central subfield thickness (CST), was maintained in UBX1325-treated patients throughout the duration of the study UBX1325 had a favorable safety and tolerability profile with no evidence of intraocular inflammation  UNITY to host investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., today, April 24 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., April

      4/24/23 7:00:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

      UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of UBX1325-treated patients did not require anti-VEGF treatment through 24 weeks Company to share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in second half of 2023 UNITY to host investor call today, March 27, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company d

      3/27/23 7:30:00 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Unity Biotechnology Inc.

      SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)

      11/14/24 4:35:22 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Unity Biotechnology Inc. (Amendment)

      SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)

      2/14/24 1:52:24 PM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Unity Biotechnology Inc. (Amendment)

      SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)

      5/10/23 9:45:10 AM ET
      $UBX
      Biotechnology: Pharmaceutical Preparations
      Health Care